Trial Profile
A first Proof-of-concept phase II study of nitazoxanide in NASH patients with advanced fibrosis.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2018
Price :
$35
*
At a glance
- Drugs Nitazoxanide (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 13 Mar 2018 According to a GENFIT media release, the Company plans to submit to the FDA an application for authorization to launch this trial in the coming months.
- 25 Sep 2017 According to a GENFIT media release, the Company plans to submit to the FDA an application for authorization to launch this trial before the end of 2017.
- 28 Apr 2017 New trial record